Mirum Pharmaceuticals (MIRM) Stock
Commercial pharmaceutical company for rare liver disease. Here's the price, business snapshot, and what's worth knowing about Mirum Pharmaceuticals in July 2026.
Mirum Pharmaceuticals (MIRM) is a clinical-stage to commercial biopharmaceutical company focused on liver diseases, particularly rare cholestatic conditions. Its research and development efforts centre on modifying bile acid pathways to address symptoms and disease progression in small patient populations. Investors should note Mirum’s growth profile hinges on successful regulatory milestones, commercialisation of its lead therapies, and the company’s ability to expand into additional indications or geographies. Like many biotech stocks, Mirum can show above-average volatility: clinical trial outcomes, reimbursement decisions and competitive developments can materially affect the share price. The company’s market capitalisation of about $3.47bn reflects investor expectations for future revenue and pipeline potential, but those expectations are uncertain. This summary is for general educational purposes only and not personalised financial advice; suitability depends on an investor’s goals, time horizon and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Mirum Pharmaceuticals' stock, believing it will increase from its current price.
Financial Health
MIRUM Pharmaceuticals shows decent revenue and cash flow, but profitability is currently low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring MIRM
Liver Disease Therapies | Next-Gen FDA Approvals
The FDA's recent accelerated approval of Gilead's Hepcludex has established the first legal treatment for a deadly liver infection known as hepatitis D. This milestone opens the door for investors to explore opportunities in companies developing innovative liver disease therapies, specialized diagnostics, and advanced patient monitoring systems.
Published: 26 May 2026
Explore BasketPharma M&A Targets (Metabolic Disease Biotechs)
Novo Nordisk's $5.2 billion acquisition of Akero Therapeutics highlights a strategic push into the MASH treatment market. This deal could trigger a wave of similar acquisitions, boosting the value of other biotech firms with promising drugs for metabolic diseases.
Published: 10 October 2025
Explore BasketMASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: 21 September 2025
Explore BasketMASH Drug Developers Could Attract M&A in 2025
Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.
Published: 19 September 2025
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: 18 September 2025
Explore BasketWhich Pharma Stocks Could Follow Wegovy's Success?
Following the FDA's approval of Novo Nordisk's Wegovy for a common liver disease, this theme focuses on pharmaceutical companies developing treatments for metabolic disorders. This development opens a new market for weight-loss drugs and signals opportunity for firms with therapies targeting related conditions.
Published: 21 August 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: 19 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Rare‑disease focus
Concentrating on small, high‑need patient groups can mean regulatory incentives and premium pricing, though market size may limit revenue upside.
Regulatory catalysts
Milestones such as approvals or label expansions can move the stock; clinical setbacks can have the opposite effect, so outcomes are binary and impactful.
Commercial execution
Scaling sales, securing reimbursement and manufacturing reliably are essential to translate approvals into sustainable revenue; execution risks remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
